Gemcitabina

Una nuova possibilita terapeutica nei tumori avanzati dell'urotelio

Translated title of the contribution: Gemcitabine: A new therapeutic possibility in advanced urothelial cancer

Mario De Lena, Vito Lorusso

Research output: Contribution to journalArticle

Abstract

Advanced urothelial cancer is considered a chemo-responsive disease. However, in spite of this, it is still considered a poor prognosis disease as the median survival of patients treated with MVAC drug-combination (methotrexate, vinblastine, doxorubicin and cisplatin) - considered the 'gold standard' in this kind of treatment - does not exceed 12 months. Moreover, the initial response rate of 72% reported by Sternberg et al. at Memorial Sloan Kettering Cancer Center, was never reported by other Authors who observed response rates around 40%. In addition, this treatment is often accompanied by severe toxicity which may sometimes overwhelm the benefit. A novel antitumor agent, gemcitabine, has been found in phase I studies, to be well tolerated and active in patients who had progressed on MVAC. Three phase II studies on bladder cancer have confirmed the high activity and low toxicity of gemcitabine reporting response rates ranging from 22.5% in pretreated patients to 30% in patients not previously submitted to cisplatin. Moreover, the combination of gemcitabine plus cisplatin in two phase II studies, obtained 41% to 75% response with moderate toxicity. A phase III ongoing study is comparing MVAC to gemcitabine-cisplatin in order to precisely define the role of this new drug in the treatment of bladder cancer.

Original languageItalian
JournalTumori
Volume83
Issue number6 SUPPL. 1
Publication statusPublished - Nov 1997

Fingerprint

gemcitabine
Cisplatin
Urinary Bladder Neoplasms
Neoplasms
Vinblastine
Drug Combinations
Therapeutics
Methotrexate
Antineoplastic Agents
Doxorubicin
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

Gemcitabina : Una nuova possibilita terapeutica nei tumori avanzati dell'urotelio. / De Lena, Mario; Lorusso, Vito.

In: Tumori, Vol. 83, No. 6 SUPPL. 1, 11.1997.

Research output: Contribution to journalArticle

@article{84055c9e240a4bfc9b69967886150b65,
title = "Gemcitabina: Una nuova possibilita terapeutica nei tumori avanzati dell'urotelio",
abstract = "Advanced urothelial cancer is considered a chemo-responsive disease. However, in spite of this, it is still considered a poor prognosis disease as the median survival of patients treated with MVAC drug-combination (methotrexate, vinblastine, doxorubicin and cisplatin) - considered the 'gold standard' in this kind of treatment - does not exceed 12 months. Moreover, the initial response rate of 72{\%} reported by Sternberg et al. at Memorial Sloan Kettering Cancer Center, was never reported by other Authors who observed response rates around 40{\%}. In addition, this treatment is often accompanied by severe toxicity which may sometimes overwhelm the benefit. A novel antitumor agent, gemcitabine, has been found in phase I studies, to be well tolerated and active in patients who had progressed on MVAC. Three phase II studies on bladder cancer have confirmed the high activity and low toxicity of gemcitabine reporting response rates ranging from 22.5{\%} in pretreated patients to 30{\%} in patients not previously submitted to cisplatin. Moreover, the combination of gemcitabine plus cisplatin in two phase II studies, obtained 41{\%} to 75{\%} response with moderate toxicity. A phase III ongoing study is comparing MVAC to gemcitabine-cisplatin in order to precisely define the role of this new drug in the treatment of bladder cancer.",
keywords = "Bladder cancer, Chemotherapy, Gemcitabine",
author = "{De Lena}, Mario and Vito Lorusso",
year = "1997",
month = "11",
language = "Italian",
volume = "83",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6 SUPPL. 1",

}

TY - JOUR

T1 - Gemcitabina

T2 - Una nuova possibilita terapeutica nei tumori avanzati dell'urotelio

AU - De Lena, Mario

AU - Lorusso, Vito

PY - 1997/11

Y1 - 1997/11

N2 - Advanced urothelial cancer is considered a chemo-responsive disease. However, in spite of this, it is still considered a poor prognosis disease as the median survival of patients treated with MVAC drug-combination (methotrexate, vinblastine, doxorubicin and cisplatin) - considered the 'gold standard' in this kind of treatment - does not exceed 12 months. Moreover, the initial response rate of 72% reported by Sternberg et al. at Memorial Sloan Kettering Cancer Center, was never reported by other Authors who observed response rates around 40%. In addition, this treatment is often accompanied by severe toxicity which may sometimes overwhelm the benefit. A novel antitumor agent, gemcitabine, has been found in phase I studies, to be well tolerated and active in patients who had progressed on MVAC. Three phase II studies on bladder cancer have confirmed the high activity and low toxicity of gemcitabine reporting response rates ranging from 22.5% in pretreated patients to 30% in patients not previously submitted to cisplatin. Moreover, the combination of gemcitabine plus cisplatin in two phase II studies, obtained 41% to 75% response with moderate toxicity. A phase III ongoing study is comparing MVAC to gemcitabine-cisplatin in order to precisely define the role of this new drug in the treatment of bladder cancer.

AB - Advanced urothelial cancer is considered a chemo-responsive disease. However, in spite of this, it is still considered a poor prognosis disease as the median survival of patients treated with MVAC drug-combination (methotrexate, vinblastine, doxorubicin and cisplatin) - considered the 'gold standard' in this kind of treatment - does not exceed 12 months. Moreover, the initial response rate of 72% reported by Sternberg et al. at Memorial Sloan Kettering Cancer Center, was never reported by other Authors who observed response rates around 40%. In addition, this treatment is often accompanied by severe toxicity which may sometimes overwhelm the benefit. A novel antitumor agent, gemcitabine, has been found in phase I studies, to be well tolerated and active in patients who had progressed on MVAC. Three phase II studies on bladder cancer have confirmed the high activity and low toxicity of gemcitabine reporting response rates ranging from 22.5% in pretreated patients to 30% in patients not previously submitted to cisplatin. Moreover, the combination of gemcitabine plus cisplatin in two phase II studies, obtained 41% to 75% response with moderate toxicity. A phase III ongoing study is comparing MVAC to gemcitabine-cisplatin in order to precisely define the role of this new drug in the treatment of bladder cancer.

KW - Bladder cancer

KW - Chemotherapy

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=22044453507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044453507&partnerID=8YFLogxK

M3 - Articolo

VL - 83

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6 SUPPL. 1

ER -